Sanofi appoints Gary Nabel CSO
This article was originally published in Scrip
Sanofi has named Dr Gary Nabel senior vice-president, chief scientific officer and deputy to the president for global R&D, effective 3 December 2012. Dr Nabel will report to Dr Elias Zerhouni, president for global R&D. He joins Sanofi from the National Institutes of Health, where he served as director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases since 1999.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.